CXCL13 and hypoparathyroidism-retardation-dysmorphism syndrome: Based on the above results regarding both structural cells (malignant epithelial cells, CAFs) and immune cells (macrophages, CD8+/CD4+ T cells), as well as the mIHC validaion conducted on 6 HRD samples and 6 HRP samples, which confirmed higher infiltration of CXCL13+ CD8+ T cells, CD4+ Treg cells and M1 macrophages in HRD, along with elevated HDAC1 expression in HRP tumors (Figure S6, Supporting Information), we aimed to propose precise treatment modalities customized to HRD and HRP patients (Figure 7).